The aim of this study was to retrospectively evaluate safety and feasibility of sirolimus (SRL) monotherapy in kidney transplant recipients. Patients older than 18 years, with monotherapy prescribed for more than 1 month and at least 6 months of follow-up were included. We analysed the data from 138 patients. Mean time period between transplantation and start of monotherapy was 6.5 +/- 4.1 years.The most frequent reason was minimization of immunosuppression followed by malignancy. Acute rejection rate was 1.4% at 12 months (two episodes). Graft and patient survival were 94.2% and 97.1% respectively. Mean follow-up after initiation of monotherapy was 29.4 months. Two patients died as a result of cardiovascular diseases and two because of malignancy. Percentage of withdrawal from monotherapy was 14%. SRL trough levels were 10.2 +/- 2.3 ng/ml at baseline and 9.6 6 +/- 3.3 ng/ml at 12 months. Mean glomerular filtration rate was 48.4 ml/min/1.73 m(2) at baseline and 47.7 ml/min/1.73 m(2) at 12 months. Proteinuria was 499.7 mg/24 h at baseline and 543 +/- 794 mg/24 h at 12 months. No significant changes in lipids, glucose, or hemoglobin occurred, although the percentage of patients treated with statins and Epo increased at the end of the follow-up. SRL monotherapy is suitable as long-term immunosuppression in selected patients with no significantly increased risk of late acute rejection.

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1432-2277.2009.00983.xDOI Listing

Publication Analysis

Top Keywords

srl monotherapy
8
acute rejection
8
+/- ng/ml
8
monotherapy
6
months
6
patients
5
sirolimus monotherapy
4
monotherapy maintenance
4
maintenance immunosuppression
4
immunosuppression multicenter
4

Similar Publications

Objective: Therapeutic interventions for epithelial ovarian cancer (EOC) have increased greatly over the last decade but improvements outside of biomarker selected therapies have been limited. There remains a pressing need for more effective treatment options that can prolong survival and enhance the quality of life of patients with EOC. In contrast to the significant benefits of immunotherapy with immune checkpoint inhibitors (CPI) seen in many solid tumors, initial experience in EOC suggests limited efficacy of CPIs monotherapy.

View Article and Find Full Text PDF

Effective targeting of somatic cancer mutations to enhance the efficacy of cancer immunotherapy requires an individualized approach. Autogene cevumeran is a uridine messenger RNA lipoplex-based individualized neoantigen-specific immunotherapy designed from tumor-specific somatic mutation data obtained from tumor tissue of each individual patient to stimulate T cell responses against up to 20 neoantigens. This ongoing phase 1 study evaluated autogene cevumeran as monotherapy (n = 30) and in combination with atezolizumab (n = 183) in pretreated patients with advanced solid tumors.

View Article and Find Full Text PDF

Objectives: Programmed cell death ligand 1 (PD-L1) expression is widely used to predict the effectiveness of PD-(L)1 inhibitors despite its imperfection. Previous studies suggested the utilization of various serum biomarkers; nonetheless, findings are inconclusive because of limited sample sizes or the focus on a single biomarker in many of these studies. This study analyzed multiplex serum biomarkers to explore their predictive ability in a large cohort of patients with advanced non-small-cell lung cancer (NSCLC) treated with a PD-L1 inhibitor in a real-world setting.

View Article and Find Full Text PDF

Despite promise of its supplementation as both monotherapy and add-on treatment in autism spectrum disorder (ASD), the biobehavioral effects of Palmitoylethanolamide (PEA) in autistic adults have never been explored so far. We discussed the cases of two autistic adults with different degrees of severity (level 1 and level 2) presenting with symptoms of psychic distress, who were treated with ultramicronized-PEA (um-PEA) 600 mg/day monotherapy for a sustained period of 4 months. The level 1 autistic patient showed improved depressive symptoms and social engagement at a 12-week follow-up, in parallel to a tendency toward reduced inflammatory response and enhanced endocannabinoid (eCB) signaling, partially relapsing after um-PEA discontinuation at four months.

View Article and Find Full Text PDF

Introduction: EGFR tyrosine kinase inhibitors have been the standard treatment for patients with NSCLC who have sensitive mutations. This study revealed final analysis survival data, biomarkers, and resistance mechanisms of osimertinib plus bevacizumab or osimertinib monotherapy in previously untreated patients with advanced -positive nonsquamous NSCLC.

Methods: We previously reported the primary results of a randomized, open-label, phase 2 study comparing osimertinib plus bevacizumab with osimertinib monotherapy for this population.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!